

## Why AT1R blockade makes sense for SARS

Sixty percent of the genomic sequence of the SARS coronavirus differs from the only two known strains of human coronavirus<sup>1,2</sup>. Human coronaviruses produce a mild “cold,” but SARS often produces acute respiratory distress syndrome (ARDS).

The novelty of coronavirus antigens apparently provokes an exaggerated immune response in the host, which explains why steroids, which depress the immune response, are of greater clinical utility in this disease than antiviral therapy<sup>3</sup>. Cytokines, especially TNF-alpha, are responsible for the early flu-like symptoms of fever, headache, myalgia seen in SARS. The high degree of fever suggests that TNF-alpha release is unusually strong. Indeed, the host's exuberant immune response to novel antigen(s) likely explains why SARS resembles the 1918 influenza pandemic in its disease severity<sup>4</sup>.

TNF-alpha is released by virally infected macrophages<sup>4,5</sup>. Macrophages express angiotensin I-converting enzyme (ACE) on their plasma membrane when they become activated, and ACE is the rate-limiting step for angiotensin II production<sup>6-8</sup>. TNF-alpha synthesis and secretion is enhanced by angiotensin II in renal macrophages, although the effect of angiotensin II on alveolar macrophages has not yet been studied<sup>9</sup>.

Virally infected alveolar type II pneumocytes and macrophages recruit additional monocytes, in part through synthesis and secretion of monocyte migration inhibitory factor (MMIF). The synthesis and release of MMIF is stimulated by angiotensin II, at least in renal tubular epithelial cells<sup>10</sup>.

Apoptosis of alveolar macrophages after viral infection amplifies the immune response and lung damage<sup>11</sup>. Alveolar apoptosis may be stimulated by angiotensin II, as in apoptosis of pulmonary epithelial cells (see below).

A major problem of SARS is that, after about a week of infection, virally infected type II pneumocytes lift off from the alveolar basement membrane leaving hyaline membranes behind, similar to the behavior of Vero cells (African green monkey kidney cells) in culture<sup>2</sup>. This process clearly involves apoptosis of the sheet of epithelial cells<sup>1,2</sup>. Type II pneumocyte apoptosis is stimulated by angiotensin II, probably acting through type 1 receptors (AT1R's)<sup>12,13</sup>. Pulmonary epithelial cell apoptosis is a common feature of the acute respiratory distress syndrome (ARDS).

Several viral diseases, including HIV, hepatitis A and B are more frequent in patients with the ACE deletion/deletion genotype (ACE D/D genotype), which is associated with overactivity of ACE<sup>7</sup>.

On pathology, SARS lung can look like organizing bronchiolitis obliterans or diffuse alveolar damage<sup>1,2</sup>. The latter is typical of acute respiratory distress syndrome (ARDS). In a mouse model, a ten-fold higher dose of virus was sufficient to convert bronchiolitis obliterans into ARDS<sup>14</sup>. Inhibition of angiotensin II should therefore be effective in the treatment of ARDS<sup>15</sup>, and SARS in particular.

However, SARS patients cannot tolerate ACE inhibition, since their blood pressure is already low because of volume depletion. A small dose of an AT1R antagonist (angiotensin II receptor blocker, or “ARB”) can inhibit T cell production of IFN-gamma and stop hair loss within 36 hours in active alopecia areata in a 14 year old girl, with only minimal lowering of blood pressure (Moskowitz DW,

unpublished case report). Apart from lowering blood pressure, ARBs have no known side effects.

A similarly small dose of an ARB should be useful for treatment of patients with established SARS, as well as prophylaxis in uninfected patients. If the above line of reasoning is correct, even a small dose of an ARB should convert infection with the SARS coronavirus into a mild disease which more closely resembles infection with one of the two known human strains of coronavirus than ARDS<sup>16</sup>.

## References

1. Drosten C, Gunther S, Preiser W, Van Der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. *N Engl J Med*. 2003 Apr 10 [epub ahead of print]; PMID: 12690091
2. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang JY, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ. A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. *N Engl J Med*. 2003 Apr 30 [epub ahead of print]; PMID: 12690092
3. JSM Peiris, CM Chu, VCC Cheng, KS Chan, IFN Hung, LLM Poon, KI Law, BSF Tang, TYW Hon, CS Chan, KH Chan, JSC Ng, BJ Zheng, WL Ng, RWM Lai, Y Guan, KY Yuen and members of the HKU / UCH SARS Study Group. Prospective study of the clinical progression and viral load of SARS associated coronavirus pneumonia in a community outbreak. (This paper has been accepted by The Lancet and will be published next week). Available at: <http://www.who.int/csr/sars/prospectivestudy/en/index.html>
4. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, Gordon S, Guan Y, Peiris JS. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? *Lancet* 2002 Dec 7;360(9348):1831-7. PMID: 12480361
5. Lehmann C, Sprenger H, Nain M, Bacher M, Gemsa D. Infection of macrophages by influenza A virus: characteristics of tumour necrosis factor-alpha (TNF alpha) gene expression. *Res Virol* 1996 Mar-Jun;147(2-3):123-130. PMID: 8901431
6. Moskowitz DW. Is "somatic" angiotensin I-converting enzyme a mechanosensor? *Diabetes Technol Ther*. 2002;4(6):841-58. PMID: 12685804
7. Moskowitz DW. Is angiotensin I-converting enzyme a "master" disease gene? *Diabetes Technol Ther*. 2002;4(5):683-711. PMID: 12458570
8. Moskowitz DW. From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. *Diabetes Technol Ther*. 2002;4(4):519-32. PMID: 12396747
9. Nakamura A, Johns EJ, Imaizumi A, Niimi R, Yanagawa Y, Kohsaka T. Role of angiotensin II-induced cAMP in mesangial TNF-alpha production. *Cytokine*. 2002 Jul 7;19(1):47-51. PMID: 12200113

10. Rice EK, Tesch GH, Cao Z, Cooper ME, Metz CN, Bucala R, Atkins RC, Nikolic-Paterson DJ. Induction of MIF synthesis and secretion by tubular epithelial cells: A novel action of angiotensin II. *Kidney Int.* 2003 Apr;63(4):1265-1275. PMID: 12631343
11. Wang L, Antonini JM, Rojanasakul Y, Castranova V, Scabilloni JF, Mercer RR. Potential role of apoptotic macrophages in pulmonary inflammation and fibrosis. *J Cell Physiol* 2003 Feb;194(2):215-24. PMID: 12494460
12. Wang R, Alam G, Zagariya A, Gidea C, Pinillos H, Lalude O, Choudhary G, Oezatalay D, Uhal BD. Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo. *J Cell Physiol.* 2000 Nov;185(2):253-9. PMID: 11025447
13. Li X, Zhang H, Soledad-Conrad V, Zhuang J, Uhal BD. Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. *Am J Physiol Lung Cell Mol Physiol.* 2003 Mar;284(3):L501-7. PMID: 12573988
14. Majeski EI, Harley RA, Bellum SC, London SD, London L. Differential role for T cells in the development of fibrotic lesions associated with reovirus 1/L-induced bronchiolitis obliterans organizing pneumonia versus Acute Respiratory Distress Syndrome. *Am J Respir Cell Mol Biol.* 2003 Feb;28(2):208-17. PMID: 12540488
15. Raiden S, Nahmod K, Nahmod V, Semeniuk G, Pereira Y, Alvarez C, Giordano M, Geffner JR. Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. *J Pharmacol Exp Ther* 2002 Oct;303(1):45-51. PMID: 12235231
16. Patent application filed by GenoMed, April 25, 2003.

David W. Moskowitz MD MA(Oxon) FACP  
Chairman, CEO and Chief Medical Officer  
GenoMed, Inc.  
St. Louis, Missouri, USA  
[www.genomedics.com](http://www.genomedics.com)  
e-mail: [dwmoskowitz@genomedics.com](mailto:dwmoskowitz@genomedics.com)

(C) Copyright DW Moskowitz MD and GenoMed, 2003.